Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2005Neurology

The incidence of neurotoxicity was significantly lower in the vitamin E group compared to controls (25% vs 73.3%, p=0.019; RR 0.34, 95% CI 0.14-0.84).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does oral vitamin E reduce chemotherapy-induced neuropathy in cancer patients receiving cisplatin or paclitaxel?

Population

31 patients with cancer treated with six courses of cumulative cisplatin, paclitaxel, or their combination…

Comparison

Oral vitamin E 600 mg/day during chemotherapy… vs No supplementation

Design

RCT, randomly assigned in two groups, open label with blind assessment

Follow-up

3 months after cessation of chemotherapy

Authors

AAAndreas A. ArgyriouECElisabeth ChroniΑKΑngelos Koutras

Discussion

Loading...

Member takes

Overview

Supports vitamin E to reduce CIPN with cisplatin/paclitaxel; extends prior data with RCT confirmation.

Structured PICO

Does oral vitamin E reduce chemotherapy-induced neuropathy in cancer patients receiving cisplatin or paclitaxel?

P
Population
31 patients with cancer treated with six courses of cumulative cisplatin, paclitaxel, or their combination regimens
I
Intervention
Oral vitamin E 600 mg/day during chemotherapy and 3 months after its cessation
C
Comparator
No supplementation
O
Outcome
Incidence and severity of neurotoxicity (measured by a modified peripheral neuropathy score)safety

Vitamin E supplementation significantly reduces the incidence and severity of chemotherapy-induced peripheral neuropathy in cancer patients.

Cite This Study

Argyriou et al. (2005) studied this question.

synapsesocial.com/papers/6a8a984d0f137e402b339d75https://doi.org/10.1212/01.wnl.0000148609.35718.7d
View Full Paper
Ask AI
Bookmark
Share